STADApharm GmbH secures contract for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient erythropoietin (exclusively Epoetin zeta), ATC B03XA01 for the period 01122024 - 30112026

Germany, July 6 -- Germany based STADApharm GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient erythropoietin (exclusively Epoetin zeta), ATC B03XA01 for the period 01122024 - 30112026 . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....